Related Experiment Video
Updated: Oct 27, 2025
Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Seeds of their own destruction: Dominant-negative peptide screening yields functional insight and therapeutic leads
Andrew Savinov1, Frederick P Roth2
1Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Abstract:
Systematic, high-throughput screening for "dominant-negative" protein fragments is an emerging method for mapping functional regions of the parental protein in vivo. In this issue of Cell Systems, Ford et al. apply this approach to 65 cancer drivers, providing functional insights and demonstrating therapeutic potential for several dominant-negative peptides.
Insights
Researchers mapped cancer driver protein functions using dominant-negative fragments. This approach revealed new therapeutic targets and potential peptide-based cancer treatments.
Area of Science:
- Molecular Biology
- Cancer Genomics
- Proteomics
Background:
- Dominant-negative protein fragments offer a powerful method for dissecting protein function in vivo.
- High-throughput screening enables systematic analysis of large protein sets.
Purpose of the Study:
- To apply dominant-negative screening to identify functional regions of cancer driver proteins.
- To explore the therapeutic potential of dominant-negative peptides derived from cancer drivers.
Main Methods:
- Systematic, high-throughput screening of dominant-negative protein fragments.
- In vivo functional analysis of protein fragments.
- Application to a panel of 65 cancer driver genes.
Main Results:
- Functional insights were gained into the roles of 65 cancer driver proteins.
- Several dominant-negative peptides demonstrated therapeutic potential.
- The study validated dominant-negative screening as a method for functional proteomic analysis.
Conclusions:
- Dominant-negative screening is an effective strategy for mapping protein function in vivo.
- This approach can identify novel therapeutic targets and peptide-based interventions for cancer treatment.
